about
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaEverolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaAlisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaFlavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaFludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasTacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerLow-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomaFludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerNivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaA Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell LymphomaAlisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaEfficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesLenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplanCombination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaCarfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaVeliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsEfficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITLAnti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell LymphomaInfection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantEfficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaPhase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell LymphomaEtoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaDeferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesPanobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaStudy of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaLenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersHigh-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaVorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaBendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaLenalidomide Maintenance Therapy After High Dose BEAM With or Without RituximabAR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaBortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaReduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesSingle or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesMethoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesRomidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaLenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
P1050
Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literatureRenal infarction due to polyarteritis nodosa in a patient with angioimmunoblastic T-cell lymphoma: a case report and a brief review of the literatureReview of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.
P921
Q61914555-5198A62B-3306-4583-A624-A21416FC7708Q61938249-B9CAB7E3-3CE8-4061-ADAE-4C5E0AFCA338Q61956260-E31381D6-1F6D-4A43-9BAF-C205ED91BBB4Q62105023-714F4BE4-B8D3-4EF7-B95A-83AB18A1B38CQ62105038-6EB5CFF2-593F-4B7D-8CC5-C6D398998C9CQ62106064-BE63E30E-1545-4977-B2BE-8CA4239D0803Q62110076-92BE3C1B-688F-4EE5-90AC-A4345DCEC09CQ62110098-C7419BA6-4C9D-4290-8B53-E98605A3CE72Q62110333-337044DC-DD19-4BF4-B1D1-92ECEDCDB5BFQ62110790-452C56A3-BA4E-410B-9AD2-FE90827D9887Q63228705-704183F9-018E-4248-A994-9EF7967288C4Q63229059-021D2459-B898-4F14-BBF4-BB5EDD1DE932Q63317912-1B2A4C34-FA9F-4F3E-855F-14F36225CCC8Q63319133-10BF0A14-4132-42F3-8181-F3E50B63CA50Q63320777-5C1BFCE4-75DE-43FB-A186-92EFEE136DEBQ63322386-F67E57F0-8811-4DE1-BA3D-34ACA5318258Q63335756-340E5590-6887-4B26-8342-D53EF11A9D3DQ63335760-36D1097D-A926-40C7-86A9-42BEA6EDF9F1Q63338899-79823BE0-E371-4873-B702-7748B134CEE7Q63395067-002A71C4-79AC-442B-8CD3-FDA865EB0131Q63571326-A651CD49-3CAB-49D6-8C12-BF68A93D71AFQ63572918-0C8617B4-7AC8-43EC-BE1A-E863D190C1ADQ63596451-5379D0ED-AB83-4A9F-BE0B-0994184344ADQ63599657-19E44A16-FA88-4F88-B113-FD4893706D1FQ63806652-6119DD25-AB84-4068-A34D-16B6A6AB27FFQ63815432-C96BA2A1-D4F7-4375-8363-48E5D423786CQ63817377-43B99907-60AD-4722-9DDD-B1644EC1050AQ63817723-632A1F33-5E76-48EA-B09C-2EF2ED6D2F00Q63818387-D782E4C5-BF2D-4ADF-9863-37CC65D6649CQ63829689-5B93EC6C-B2B0-4F75-9939-9C83374E6CF5Q63831582-007D5380-B3FB-4900-8186-C17BA8076A31Q63833225-656ADE04-A585-41FB-BA70-15F5261A4E46Q63835402-A2704829-28C4-40A5-A6A0-390E0359B07AQ63836492-54C67B04-ACB4-4479-A46A-A6B7F315AF5FQ63836506-CE45BFF6-235E-4746-9A9E-C34FF0DAB819Q63836792-834B3F34-E647-44C0-AA78-3F4ABA5A8A52Q63838272-233AA163-AF38-4DCB-9899-D42E993FEC5BQ63840494-824A8DCB-EA21-4018-A1E3-9FF9AFE53487Q63843988-04558BC6-BB49-4A0E-9D98-A0BAA2B9CBD8Q64042044-62DA5B68-7798-4DA6-B30F-BD9688E5D7D6
P1050
description
disorder characterized by prol ...... dophilic interstitial material
@en
name
immunoblastic lymphadenopathy
@en
lymphadénopathie immunoblastique
@fr
type
label
immunoblastic lymphadenopathy
@en
lymphadénopathie immunoblastique
@fr
prefLabel
immunoblastic lymphadenopathy
@en
lymphadénopathie immunoblastique
@fr
P672
P486
P1995
P31
P486
P672
C15.604.338.500
C15.604.515.509
C20.683.515.501